—
C+
C+ The full Closelook — membership. Open the C+ overview

Dr. Reddy’s Laboratories Ltd ADR (RDY) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Dr. Reddy’s Laboratories Ltd ADR

RDY in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Dr. Reddy's Laboratories makes and sells prescription and over-the-counter medicines, running three segments: Global Generics for branded and generic finished drugs, PSAI for active pharmaceutical ingredients and contract research, and an Others unit developing oncology and inflammation therapies. It covers therapeutic areas from cardiovascular and diabetes to dermatology and pain management. The company is headquartered in Hyderabad, India, and lists in the US through American Depositary Shares.
Where it sits in the stack
Dr. Reddy's carries no seat in our index and sits outside the layers the diary maps for the AI build-out; it belongs instead to the diary's broader pharmaceutical coverage, tracked as a generics and active-ingredients manufacturer rather than as an infrastructure name.
Who it is priced against
Closelook's peer group is not set for this name; by industry it sits with other specialty and generic drug manufacturers, and the market names Teva Pharmaceutical Industries as a comparable generics maker.
Why Closelook tracks it
It carries a Closelook score, with the momentum module the one the diary flags, though the reading can shift nightly; it holds no index seat and no diary quotes so far.
What the diary watches
Whether the shares stabilise against their 50-day and 200-day averages after trading well off the 52-week high, which would change how the diary reads the momentum module.

Dr. Reddy’s Laboratories Ltd ADR (RDY) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for RDY, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against RDY on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 1.21%, semi-annual · last 0.0830 USD on 2026-07-24

Dividends and capital return

What RDY pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.15 USD per share · a 1.21% yield on the 2026-09-17 close 2 distributions, paid twice a year 2026-09-17
  • Change on the year +61.0% against the prior twelve months prior twelve months 0.0915 USD per share
  • Last distribution 0.0830 USD per share as the price series records it, within days of the ex-date 2026-07-24
  • By calendar year 2025: 0.0915 USD (partial) · 2026: 0.15 USD to date first distribution recorded in the three-year window: 2025-07-25

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Dr. Reddy’s Laboratories Ltd ADR (RDY)?

Dr. Reddy’s Laboratories Ltd ADR trades as RDY on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is RDY in a Closelook index?

Not currently — Dr. Reddy’s Laboratories Ltd ADR is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does RDY trade against its moving averages?

Recovery attempt under the 200-day: Trades +0.2% vs the 50-day and -8.1% vs the 200-day average, 21.4% below the 52-week high and +8.1% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Dr. Reddy’s Laboratories Ltd ADR do?

Dr. Reddy's Laboratories makes and sells prescription and over-the-counter medicines, running three segments: Global Generics for branded and generic finished drugs, PSAI for active pharmaceutical ingredients and contract research, and an Others unit developing oncology and inflammation therapies. It covers therapeutic areas from cardiovascular and diabetes to dermatology and pain management. Closelook's peer group is not set for this name; by industry it sits with other specialty and generic drug manufacturers, and the market names Teva Pharmaceutical Industries as a comparable generics maker.

Where does Dr. Reddy’s Laboratories Ltd ADR sit in the AI build-out?

Dr. Reddy's carries no seat in our index and sits outside the layers the diary maps for the AI build-out; it belongs instead to the diary's broader pharmaceutical coverage, tracked as a generics and active-ingredients manufacturer rather than as an infrastructure name. It carries a Closelook score, with the momentum module the one the diary flags, though the reading can shift nightly; it holds no index seat and no diary quotes so far.

Does Dr. Reddy’s Laboratories Ltd ADR pay a dividend?

Dr. Reddy’s Laboratories Ltd ADR has paid 0.15 USD per share over the last twelve months, paid twice a year, a trailing yield of 1.21% on the 2026-09-17 close; the last distribution recorded in the price series was 0.0830 USD on 2026-07-24. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for RDY, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.